MetaVia Inc. MTVA
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2016-08-05
MetaVia Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D expense | $6.8M | $21.6M | — | — | — | — | — | — | — | — |
| Operating income | -$13.7M | -$28.8M | -$15.9M | -$19.6M | -$15.3M | -$29.7M | -$20.2M | -$15.5M | -$33.1M | -$14.7M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$13.0M | -$27.6M | -$12.5M | -$14.0M | -$15.3M | -$29.7M | -$21.3M | -$15.5M | -$33.4M | -$14.6M |
| EPS (diluted) | $-7.35 | $-39.13 | $-2.46 | $-43.42 | $-19.81 | $-1.83 | — | — | — | — |
| Operating cash flow | -$15.7M | -$24.7M | -$10.8M | -$11.7M | -$15.1M | -$10.8M | -$7.0M | -$14.5M | -$26.9M | -$11.0M |
| Free cash flow | -$15.7M | -$24.7M | -$10.8M | — | -$15.1M | -$10.8M | -$7.3M | -$14.5M | — | — |
| Cash & equivalents | $10.3M | $16.0M | $22.4M | $33.4M | $16.4M | $10.1M | $13.9M | $2.8M | $18.5M | $24.0M |
| Total assets | $11.1M | $16.3M | $22.8M | $33.5M | $16.8M | $11.0M | $14.5M | $3.8M | $19.0M | $24.8M |
| Total liabilities | $5.8M | $8.3M | $6.1M | $11.8M | $2.2M | $3.8M | $2.2M | $360,000 | $15.1M | $4.1M |
| Shareholders' equity | $5.3M | $7.9M | $16.7M | $21.8M | $14.6M | $7.2M | $12.3M | -$13.3M | $25,000 | $20.6M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.